Document Detail


Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.
MedLine Citation:
PMID:  16287090     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Resistance to anticancer drugs is the major problem in the treatment of many advanced cancers, including androgen-independent prostate cancer. Recently, increased expression of Id-1, a basic helix-loop-helix protein, is reported in several types of advanced cancer. It is suggested that high expression of Id-1 may provide an advantage for cancer cell survival and inactivation of Id-1 may be able to increase cancer cells' susceptibility to apoptosis. To test this hypothesis, in this study, by using RNA interfering technology, we inactivated the Id-1 gene in 2 androgen-independent prostate cancer cell lines, DU145 and PC3, and investigated whether downregulation of Id-1 could lead to increased sensitivity to a commonly used anticancer drug, taxol. By using colony forming assay and MTT assay, we found that inactivation of Id-1 resulted in both decreased colony forming ability and cell viability in prostate cancer cells, after taxol treatment. In addition, the si-Id-1-induced sensitization to taxol was associated with activation of apoptosis pathway, which is demonstrated by increased apoptotic index, DNA laddering, sub-G1 phase of the cell cycle, as well as cleaved-PARP and Caspase 3. Furthermore, c-Jun N-terminal kinase (JNK), one of the common pathways responsible for taxol-induced apoptosis, was also activated in the si-Id-1 transfected cells. Inhibition of JNK activity by a specific inhibitor, SP600125, blocked the si-Id-1-induced sensitivity to taxol. These results indicate that increased Id-1 expression in prostate cancer cells may play a protective role against apoptosis, and downregulation of Id-1 may be a potential target to increase sensitivity of taxol-induced apoptosis in prostate cancer cells.
Authors:
Xiaomeng Zhang; Ming-Tat Ling; Xianghong Wang; Y C Wong
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  118     ISSN:  0020-7136     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-02-21     Completed Date:  2006-04-18     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2072-81     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2005 Wiley-Liss, Inc.
Affiliation:
Cancer Biology Group, Department of Anatomy, Faculty of Medicine, The University of Hong Kong, Hong Kong.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / pharmacology*
Apoptosis
Cell Survival
Down-Regulation
Drug Resistance, Neoplasm
Enzyme Activation
Gene Expression Profiling
Humans
Inhibitor of Differentiation Protein 1 / biosynthesis*,  physiology
MAP Kinase Kinase 4 / metabolism*
Male
Paclitaxel / pharmacology*
Prostatic Neoplasms / pathology*
RNA Interference*
Tumor Cells, Cultured
Up-Regulation
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Inhibitor of Differentiation Protein 1; 33069-62-4/Paclitaxel; EC 2.7.12.2/MAP Kinase Kinase 4

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prediction of transporter family from protein sequence by support vector machine approach.
Next Document:  Investigation of the functional three-dimensional anatomy of the human cystic duct: a single helix?